tbuckley/cabot-search huggingface dataset:
Suicidal ideation and suicide attempts among patients with panic disorder: a survey of two outpatient clinics
Authors: S Friedman, J C Jones, L Chernen, D H Barlow
Journal: American Journal of Psychiatry (1992)

Recent epidemiologic studies found that 20% of subjects with the diagnosis of panic disorder had attempted suicide. This study sought to determine the prevalence of suicidal ideation and suicide attempts among patients with panic disorder and whether the presence of comorbid borderline personality disorder influenced the prevalence of suicidal thoughts and behavior.At two outpatient clinics, experienced clinicians conducted retrospective reviews of data from the intake interviews and charts of 59 patients with panic disorder and comorbid borderline personality disorder and 234 patients with panic disorder with or without axis II disorders other than borderline personality disorder.Suicide attempts were reported by 2% of the patients with panic disorder, compared to 25% of the patients with both panic disorder and borderline personality disorder. In addition, 2% of the patients with panic disorder, compared to 27% of the patients with panic disorder and borderline personality disorder, reported suicidal ideation that was judged to be of clinical significance.The rate of suicidal ideation and suicide attempts for psychiatric outpatients with panic disorder was discrepant with the findings of the earlier studies. The increased suicide risk in this group of patients was associated with borderline personality disorder, increased substance abuse, and affective instability. While 61% of the panic disorder patients and 78% of the patients with both panic disorder and borderline personality disorder reported thinking about death, this must be distinguished from actual suicidal ideation and clinical risk of suicide.
Abstract P304: Fatty liver disease is Associated with Aortic Valve Sclerosis in the General Population
Authors: Wolfgang Lieb, Marcello R Markus, Sebastian E Baumeister, Henri Wallaschofski, Marcus Dörr, Henry Völzke
Journal: Circulation (2012)

Background: Fatty liver disease has been linked to increased cardiovascular risk and mortality, but the precise mechanisms are incompletely understood. We aimed to assess whether fatty liver disease is associated with aortic valve sclerosis in the community. Methods: Cross-sectional data (1,150 men and 1,087 women, aged 45–81 years) from the population-based Study of Health in Pomerania (SHIP), in northeast Germany, were analyzed. Fatty liver disease was defined as a hyperechogenic ultrasound pattern of the liver in conjunction with increased serum alanine aminotransferase levels. Aortic valve sclerosis was determined by echocardiography and defined as an abnormal irregular thickening and a focal or diffuse increase of the echogenicity of the leaflets. Results: The prevalences of fatty liver disease and aortic valve sclerosis were 15.6% and 32.5%, respectively. Among participants with fatty liver disease, aortic valve sclerosis was much more common than in indivivuals without fatty liver disease (prevalence aortic valve sclerosis 38.3% vs. 29.2%; p=0.001). Upon adjustment for confounding factors (including age, sex, waist circumference, alcohol consumption, physical activity, systolic blood pressure, antihypertensive medication, total/HDL cholesterol ratio, lipid-lowering medication, HBA1c, anti-diabetic medication, and estimated glomerular filtration rate), individuals with fatty liver disease had 38% higher odds ratio of presenting with aortic valve sclerosis as compared to those without fatty liver disease (95% confidence interval, OR 1.02 to 1.88). Conclusions: Our findings are consistent with the hypothesis that fatty liver disease is associated with aortic valve sclerosis, independently of classic cardiovascular risk factors. Metabolic changes secondary to fatty liver disease may have a pro-atherogenic effect promoting the development of the aortic valve calcification and sclerosis.
Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-I receptor, in patients with multiple myeloma or solid tumors
Authors: D. Yin, M. L. Paccagnella, M. Q. Lacy, J. S. De Bono, P. Haluska, A. Gualberto, A. Sharma
Journal: Journal of Clinical Oncology (2008)

2524 Background: CP-751,871, a fully human IgG2 monoclonal antibody against the insulin-like growth factor type I receptor (IGF-IR), is currently under clinical development for cancer treatment. The aim of the present work was to develop a population model for characterizing the pharmacokinetics (PK) of CP-751,871 in cancer patients. Methods: CP-751,871 concentration-time data were obtained from 34 patients with multiple myeloma and 46 patients with solid tumors, who received escalating doses of CP-751,871 via intravenous infusions in the dose range of 0.1 to 20 mg/kg. Nonlinear mixed effects modeling was conducted using NONMEM to obtain the structural model describing CP-751,871 disposition and the statistic models describing intra- and inter-patient variabilities. Possible covariates contributing to inter-patient PK variability were also explored. Results: A mechanism-based structural PK model with a saturable elimination process best described the disposition of CP-751,871 in cancer patients. For variance models, inter-patient variability in PK disposition parameters was described by an exponential error model, and the residual variability was best described by a log-normal additive residual error model. Body weight was identified as a covariate for the initial distribution volume and the plasma clearance parameters. Age, sex, and albumin or bilirubin concentrations showed no apparent effects on CP-751,871 PK. In addition, there was no apparent difference in PK between multiple myeloma and solid tumor patients. Conclusions: A population PK model was developed to describe the concentration-time profiles of CP-751,871 in cancer patients. The identification of body weight as a significant covariate for plasma clearance validates the appropriateness of body weight-based dosing for CP-751,871. The population PK model can be applied to further explore pharmacokinetic/pharmacodynamic (PK/PD) relationships of CP-751,871 in cancer patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Oncology Pfizer Oncology Pfizer Oncology Pfizer Oncology
Variation in the ribosomal internal transcribed spacers (ITS1 and ITS2) among eight taxa of the Mimulus guttatus species complex.
Authors: C E Ritland, K Ritland, N A Straus
Journal: Molecular Biology and Evolution (1993)

The internal transcribed spacer region (ITS1 and ITS2) of the 18S-25S nuclear ribosomal DNA sequence and the intervening 5.8S region were sequenced from three individuals in each of eight taxa of the Mimulus guttatus species complex. Three discrete variants, or "types," of ITS sequences were found, among which 30%-40% of sites differed, compared with 1%-2% within types. Dot plots indicate that these types were not related by conspicuous rearrangements or inversions. More than one ITS type was often found in the same taxon, and two of three ITS types span species boundaries, indicating their presence prior to speciation. These ITS sequences showed essentially no positional homology with the nearest sequenced relative, tomato. In contrast, the 5.8S region was relatively unvaried, with 8 of 162 sites varied in the sample among all eight taxa. The phylogeny inferred by the most common ITS sequence type, rooted by the two other ITS types, agreed with isozymes in showing the distinctness of M. nudatus, M. laciniatus, and M. tilingii from the other five taxa.
Clinicopathologic and prognostic features of triple-negative breast cancer analyzed in registration data of the Japanese Breast Cancer Society, 11705 cases
Authors: H. Iwase, Y. Yamamoto, J. Kurebayashi, H. Tsuda, T. Ota, M. Kurosumi, K. Miyamoto, T. Iwase
Journal: Journal of Clinical Oncology (2009)

e22122 Background: Triple-negative (TN) breast cancers which are negative for ER, PgR, and HER2 by immunohistochemistry are associated with a poor prognosis. To clarify the characteristics of TN tumors, the data of the registration committee of the Japanese Breast Cancer Society were analyzed with respect to clinicopathologic factors, response to neoadjuvant chemotherapy (NAC) and prognosis. Methods: Of 14,748 cases that were registered in 2004, 11,705 cases (79.4%) were examined for ER, PgR, and HER2 status, which was based on local institute. In the 2,331 cases of all registered cases, the prognosis and details of the treatment were analyzed with 47.8 months as median follow-up period. In 184 cases (7.9%), NAC was mainly performed using anthracycline and taxane based chemotherapy. Results: Luminal A type with positive for ER and/or PgR and negative for HER2 was most prevalent (53.8%), followed by TN type (15.5%). TN cancers were diagnosed at a slightly advanced stage and more of the cases had lymph node metastases compared to other types. Mucinous or tubular carcinoma was frequently seen in the Luminal A type. Squamous cell, spindle cell carcinoma, or metaplastic carcinoma with bone/cartilage metaplasia was found in only TN type. The HER2 type and TN type had statistically worse outcome compared to Luminal type in DFS and OS (P&lt;.0001 and P&lt;.0001, respectively). Pathological response rate of NAC, including grade 2 and 3, was higher in TN tumor as 51.5 % (22/53) than in Luminal A tumor as 16.7% (12/72). Responders in TN tumors have a better prognosis than non-responder (P=.0016), but this tendency was not recognized in non-TN tumors (P=.15). Conclusions: The ratio of the TN tumors in Japan was 15–6%. Central reviews of immunohistochemistry, such as ER, PgR, HER2, CK5/6, EGFR etc, will be confirmed in this cohort, for TN tumors are similar to basal-like tumors discriminated by gene- profiling. [Table: see text]
Interim results of a survey to evaluate use and interest in autologous and allogeneic bone marrow transplant as a treatment option among patients
Authors: M. Van Hoef
Journal: Journal of Clinical Oncology (2009)

e17569 Background: A survey was placed on websites inviting patients to provide an opinion about bone marrow transplant as treatment option for their disease. Herein an interim analysis of results is presented. Methods: A survey was developed requesting general information about the responder, the disease, and the experience with and interest in autologous and allogeneic donor transplants as treatment option for disease. The survey was placed on sites in the Netherlands and Belgium (cancer fora and website) and was initially announced in a few magazins. Results: Several cancer fora in the Netherlands initially rejected the survey; in Belgium no restrictions were encountered. At the interim analysis 81 Dutch and 2 English speaking responders have started the survey. 60 Dutch and 1 English speaking responder completed the survey as of December 1, 2008. Of Dutch responders 60.5% accessed the survey from the website, 79.9% were women, 56% were patient. Among responders 18.7% responded related to leukemia, and the remaining to other diseases among which myeloma (10.7%), lymphoma (13.3%) and breast cancer (19.4%). The majority had been diagnosed in 2006 and 2007. The majority of responders had not been treated with autologous or allogeneic transplants (for both 87%), however 43.8% informed to know what and autologous transplant is and 55.2% knew what an allogeneic transplant is. About 25% of responders of either type had spoken about transplant with a doctor and about 35% of responders of either type thought that BMT is a treatment option for their disease. 76% of responders were aware that people can be a bone marrow donor. Conclusions: 20 questions were asked and answered; 75% of responders completed the survey. Interim results gave among others insight in knowledge, treatment. and discussion of transplant as treatment option with doctors. An update and further details will be presented. No significant financial relationships to disclose.
Topotecan, paclitaxel, and carboplatin in advanced ovarian cancer: A phase II trial of the Minnie Pearl Cancer Research Network
Authors: J. D. Zubkus, J. D. Hainsworth, D. R. Spigel, J. F. Patton, D. L. Shipley, M. Baskette, F. Schnell, F. A. Greco
Journal: Journal of Clinical Oncology (2006)

15015 Background: Topotecan (T) is standard therapy for patients (pts) with relapsed platinum refractory ovarian cancer (OC). The addition of T to paclitaxel/carboplatin (PC) may improve the first-line therapy for pts with stage III/IV OC. Methods: The primary endpoints were to assess the toxicity and response rate of TPC in previously untreated pts with advanced OC. Pts with previously untreated stage III/IV OC with performance (PS) 0 or 1, normal hematologic and organ function were eligible. Topotecan 1mg/m 2 per day IV days 1, 2, and 3; paclitaxel 175mg/m 2 IV on day 3 and carboplatin (AUC=5) IV on day 3 were administered at 21-day intervals for 6 cycles with standard dose modifications for toxicities. Responses were assessed clinically after 2 cycles and at completion of therapy. Second look laporatory (SLL) was required for pts without evaluable tumor. Results: 50 pts were enrolled: age range 27–79 (median 63); performance status 0=16, 1=34; suboptimal debulking surgery (tumor &gt; 1 cm) 32; 70% high grade tumors. Intent to treat response rates: complete response (CR) 20 pts (40%); partial response (PR) 12 pts (24%); stable (S) 13 pts (26%); progression 2 pts (4%); not evaluable 3 pts (6%). 13 pts had SLL with 5 CR, 5 PR and 3 S. Toxicities included: grade 3/4 neutropenia/thrombocytopenia 84%/44%; grade 3/4 fatigue/infection 10%/10%; no treatment-related deaths. Median progression-free survival (PFS) for all pts was 13.6 months and 1-, 2-, 3-year PFS 60%, 42%, 36%. Median survival 33.9 months for all pts with 1-, 2-, 3-year survivals 90%, 65%, 49%. Conclusions: The combination of TPC is active and relatively well tolerated with PC given on day 3. The response rates, PFS, and survivals appear similar to standard regimens. Randomized prospective trials will be required to determine the value of T added to PC for first-line therapy of advanced OC. [Table: see text]
Characteristics of Long-Term Marmoset Cell Cultures Spontaneously Altered or Transformed by Rous Sarcoma Virus&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Marczynska, Barbara, Treu-Sarnat, Gabriela, Deinhardt, Friedrich
Journal: JNCI Journal of the National Cancer Institute (1970)

Journal Article Characteristics of Long-Term Marmoset Cell Cultures Spontaneously Altered or Transformed by Rous Sarcoma Virus Get access Barbara Marczynska, Barbara Marczynska Departments of Microbiology, Presbyterian-St. Luke's Hospital and University of Illinois, Medical and Graduate College, Chicago, Illinois 60612 Search for other works by this author on: Oxford Academic PubMed Google Scholar Gabriela Treu-Sarnat, Gabriela Treu-Sarnat Departments of Microbiology, Presbyterian-St. Luke's Hospital and University of Illinois, Medical and Graduate College, Chicago, Illinois 60612 Search for other works by this author on: Oxford Academic PubMed Google Scholar Friedrich Deinhardt Friedrich Deinhardt Departments of Microbiology, Presbyterian-St. Luke's Hospital and University of Illinois, Medical and Graduate College, Chicago, Illinois 60612 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 44, Issue 3, March 1970, Pages 545–572, https://doi.org/10.1093/jnci/44.3.545 Published: 01 March 1970 Article history Received: 27 August 1969 Accepted: 05 November 1969 Published: 01 March 1970
Curative intended radiation therapy for young patients with invasive uterine cervical carcinoma: Clinical outcomes in 105 patients in a Japanese multi-institutional study
Authors: Y. Niibe, T. Ariga, T. Kazumoto, T. Kodaira, H. Etou, O. Suzuki, R. Kinoshita, K. Tsujino, M. Takemoto, K. Hayakawa
Journal: Journal of Clinical Oncology (2009)

e16558 Background: Recently, the number of young patients with invasive uterine cervical carcinoma is increasing in Japan because of earlier sexual activity and low rate of receiving screening test of uterine cervical carcinoma in Japan. However, no large studies have been performed so far to evaluate the clinical outcomes of curative intended radiation therapy for young patients with invasive uterine cervical carcinoma in Japan. Then, the current study was designed. Methods: One hundred and five patients under 40 years old were registered in the mulitiinstitutional study. The median age was 34.5 years old (range: 24–39 years old). According to FIGO, clinical stage was as follows. Stage Ib/IIa/IIb/IIIa/IIIb/IVa were 10/4/38/2/47/3, respectively. The median maximal tumor diameter was 5.5 cm (range: 2–9.2 cm). Curative intended radiation therapy was the combination of high-dose rate intracavitary brachytherapy (HDR-ICBT) combined with external beam radiation therapy (ERT). The total dose of ERT ranged from 44 Gy to 68 Gy. The total dose of HDR-ICBT to point A ranged from 12 Gy to 48 Gy. Eighty five patients received chemotherapy. Results: The 5-year overall survival rate and local control rate of all patients was 58.4 % and 59.3 %, respectively. The 5-year overall survival rates of stage Ib/IIa/IIb/IIIa/IIIb/IVa were 90.0 %/not available (NA)/73.8%/100%/37.4%/0%, respectively. The 5-year local control rates of Stage Ib/IIa/IIb/IIIa/IIIb/IVa were 80.0 %/50.0 %/73.8 %/100 %/54.6 %/NA, respectively. Sixteen patients experienced grade 3 or greater late radiation morbidity. Conclusions: Clinical outcomes of stage I-II in the young were equivalent to the Japanese standard treatment results of all ages. However, clinical outcomes of stage IIIb and IVa in the young were worse than those of all ages (5-year OS of all ages in Japan: IIIb: 50 %, IVa: 25 %). No significant financial relationships to disclose.
Prognostic factors for patients with metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens
Authors: Y. Tsai, C. Lin, C. Hsu, K. Huang, C. Huang, A. Cheng, N. J. Vogelzang, Y. Pu
Journal: Journal of Clinical Oncology (2006)

14583 Background: Combination of cisplatin and 5-fluorouracil (5-FU) has activity in metastatic urothelial carcinoma (UC). To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series, long-term survival, as a function of known and suspected prognostic variables, was determined. Methods: The survival status of 79 patients with metastatic urothelial cancer treated on two phase II trials of cisplatin and 5-FU-based regimens was updated. P-HDFL regimen (n = 35) was cisplatin 35 mg/m 2 IV 24hr D1, 8; 5-FU 2,600 mg/m 2 and leucovorin 300 mg/m 2 IV 24hr D1, 8, 15; repeated every 28 days (Cancer 2006, in press). TP-HDFL regimen (n = 44) was paclitaxel 70 mg/m 2 IV 1hr D1, 8; cisplatin 35 mg/m 2 IV 24hr D1, 8; 5-FU 2,000 mg/m 2 and leucovorin 300 mg/m 2 IV 24hr D1, 8; repeated every 21 days (Proc ASCO 22:407b, 2003 [abstr 1637]). Univariate and multivariate Cox proportional hazards models were constructed. Results: Karnofsky performance status (KPS) &lt;80%, presence of visceral metastasis, and alkaline phosphatase ≥220 U/l are three significant poor prognostic factors for survival. The percentage of patients who harbored zero-risk, one- or two-risk, and three-risk categories was 27%, 61%, and 13%, respectively. Among patients with no risk factors, the median survival time was not reached yet after a median follow-up of 43.0 months. Patients with one or two risk factors had a median survival duration of 12.3 months (95% CI 8.6–16.0). Patients with all three risk factors had a median survival of 4.6 months (95% CI 1.4–7.9). There was a significant difference in survival between the three groups (P &lt; .0001). Conclusions: Previously described prognostic factors, including KPS &lt;80%, visceral metastasis, and alkaline phosphatase ≥220 U/l, for survival in metastatic UC were confirmed in patients treated with cisplatin and 5-FU-based regimen. No significant financial relationships to disclose.
Telephone-based health coaching for cognitive, affective, and quality-of-life improvement in patient-caregiver cancer survivorship: A mixed-methods educational intervention.
Authors: D. R. Close
Journal: Journal of Clinical Oncology (2010)

TPS273 Background: Cancer survivors struggle with cognitive, affective, and physical adaptation. However, they rarely attend self-management groups to enhance behavioral skills. This pilot study tests the efficacy of a couple-oriented health coaching (HC) intervention directed to personal and interpersonal strengths impacting adaptation to cancer. Methods: An embedded experimental mixed methods design integrates intervention results with experience description. Eligible adult patient-caregiver couples (N = 100), who are planning first time cancer chemotherapy for new or recurrent cancer and who have been randomized to the intervention arm, will be scheduled for HC introduction and education with a research staff member. HC will consist of weekly telephone sessions for the four month study duration. Couples randomized to the standard of care (SOC) intervention will receive weekly telephone SOC educational sessions usual for those initiating chemotherapy. Self-report questionnaire data for the primary outcome variables will be collected pre-randomization (Time 1) and monthly by telephone interview (Time 2-Time 5). Couple members will be provided with personal health journals in which to record aspects of each week's personal cancer experience and will bring their journals with them to each medical visit. Health coaching effectiveness will be determined by repeated measures modeling of the primary outcomes (self-efficacy, self-regulation, attachment security, and health-related quality of life) for intervention group differences, within and between couple variation, and rates of change. Covariates will include baseline demographic and health variables. Thematic analysis of journal data will describe personal and interpersonal cancer experience over time. Integrated data analysis will focus on the effectiveness of health coaching in development of self-regulation for positive support of couples' cancer experiences; what experiences stabilize, accelerate or decelerate changes in the primary outcomes; and whether changes in the outcome variables contribute to couples' resilience in cancer experience. No significant financial relationships to disclose.
Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy
Authors: J A Gómez-Puerta, R Sanmartí, J R Rodríguez-Cros, J D Cañete
Journal: Annals of the Rheumatic Diseases (2004)

We read the recent article by van Vollenhoven et al 1 on the efficacy of one tumour necrosis factor α antagonist (infliximab or etanercept) when the other has failed with great interest. The authors concluded that infliximab is efficacious in a significant proportion of patients who have not responded to etanercept. No conclusive results were reported when they analysed the opposite situation, probably because 11 of the 13 patients who switched from …